Clinical trial
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
NCT03162783 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 15, 2017
- Completion date
- July 6, 2017
- Enrollment
- 51 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.